comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Beyond glycemia: to analogues | Reviews in Endocrine Metabolic Disorders GLP-1 receptor agonist versus DPP-4

Helping patients opt in for companies persistency programs may help them remember to take injections, get refills, and contact providers if clinical concerns occur

Saxenda is a 3 mg subcutaneous injection to be used daily 1x in the abdomen, thigh, or arm

A large and increasing share of the public say they have heard about GLP-1 drugs, with about eight in ten (82%) adults saying they have heard at least a little and about three in ten (32%) saying they have heard a lot about these drugs

Therefore there is an unmet need for therapeutics which can result in a clinically meaningful reduction in ICP without side effects which compromise cognition

Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment

In Your Brain GLP-1 boosts dopamine, helping with weight management and possibly treating certain addictive behaviors